NAREB
Nanotherapeutics for antibiotic resistant emerging bacterial pathogens
| Coordinatore | INSTITUT PASTEUR
Organization address
address: RUE DU DOCTEUR ROUX 25-28 contact info |
| Nazionalità Coordinatore | France [FR] |
| Totale costo | 13˙071˙859 € |
| EC contributo | 9˙674˙158 € |
| Programma | FP7-NMP
Specific Programme "Cooperation": Nanosciences, Nanotechnologies, Materials and new Production Technologies |
| Code Call | FP7-NMP-2013-LARGE-7 |
| Funding Scheme | CP-IP |
| Anno di inizio | 2014 |
| Periodo (anno-mese-giorno) | 2014-02-01 - 2018-01-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
INSTITUT PASTEUR
Organization address
address: RUE DU DOCTEUR ROUX 25-28 contact info |
FR (PARIS CEDEX 15) | coordinator | 1˙243˙190.80 |
| 2 |
NANOIMMUNOTECH SL
Organization address
address: PLAZA FERNANDO CONDE MONTERO-RIOS 9 contact info |
ES (Vigo) | participant | 1˙019˙702.00 |
| 3 |
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Organization address
address: RUE LEBLANC 25 contact info |
FR (PARIS 15) | participant | 968˙521.00 |
| 4 |
BIOASTER FONDATION DE COOPERATION SCIENTIFIQUE
Organization address
address: AVENUE JEAN JAURES 321 BATIMENT DOMILYON contact info |
FR (LYON) | participant | 858˙776.20 |
| 5 |
STIFTELSEN SINTEF
Organization address
address: Strindveien 4 contact info |
NO (TRONDHEIM) | participant | 845˙282.00 |
| 6 |
GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL
Organization address
address: C/ SANTIAGO GRISOLIA 4 contact info |
ES (TRES CANTOS) | participant | 810˙480.00 |
| 7 |
PROCARTA BIOSYSTEMS LIMITED
Organization address
address: BANKSIDE 300 PEACHMAN WAY contact info |
UK (NORWICH) | participant | 791˙928.00 |
| 8 |
UNIVERSIDAD DE ZARAGOZA
Organization address
address: CALLE PEDRO CERBUNA 12 contact info |
ES (Zaragoza) | participant | 653˙114.00 |
| 9 |
FORSCHUNGSZENTRUM BORSTEL
Organization address
address: Parkallee 1-40 contact info |
DE (BORSTEL) | participant | 599˙855.00 |
| 10 |
CORIS BIOCONCEPT SPRL
Organization address
address: RUE JEAN SONET 4A PARC SCIENTIFIQUE CREALYS LES ISNES contact info |
BE (Gembloux) | participant | 512˙824.00 |
| 11 |
INSERM - TRANSFERT SA
Organization address
address: Rue Watt 7 contact info |
FR (PARIS) | participant | 479˙044.00 |
| 12 |
UNIVERSITEIT UTRECHT
Organization address
address: Heidelberglaan 8 contact info |
NL (UTRECHT) | participant | 370˙802.00 |
| 13 |
KUECEPT LIMITED
Organization address
address: STATION CLOSE 16-17 contact info |
UK (POTTERS BAR HERTS) | participant | 227˙528.00 |
| 14 |
NARODOWY INSTYTUT LEKOW
Organization address
address: ULICA CHELMSKA 30/34 contact info |
PL (WARSZAWA) | participant | 213˙262.00 |
| 15 |
Department of Health
Organization address
address: "Quarry House, Quarry Hill" contact info |
UK (Leeds) | participant | 79˙849.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Increase in antibiotic resistance is a global concern worldwide. The project NAREB's main objective is the optimization of several nanoformulations of antibacterial therapeutics in order to improve the therapy of multi-drug resistant (MDR) tuberculosis (TB) and MRSA infections in European MDR patients.
NAREB will address the problem of drug bioavailability inside the infected macrophages, transport across the bacterial cell wall, and avoidance of escape mechanisms (expressed by the pathogen). The success of the utilization of nanoparticles in the improvement of drug targeting in other diseases opens the way for novel applications in nanotechnology-based treatments aimed at controlling MDR-TB and MRSA.
Specific objectives to achieve the main goal are: (i) Screening of different combinations of antibiotic drugs (small chemical molecules and/or biomacromolecules - glycopeptides) with nanocarriers (lipid, polymeric, biopolymeric); (ii) Loading of Transcription Factor Decoys (TFDs) designed to block the expression of essential bacterial genes in compatible nanoparticle systems and their testing as novel antibacterials; (iii) In vitro and in vivo testing of the best therapeutic combinations in relevant experimental models and using innovative bioimaging; (iv) Improved formulations of multifunctional particles containing selected antibiotics and TFDs for increasing the bioavailability of active molecules in the site of infection (targeting strategy, adapted route of administration) (v) Assessing safety, regulatory and production (GLP/GMP) aspects in relation with the most promising nanoformulations; (vi) Clinical Development Plan for the preparatory work for the subsequent clinical testing of the selected nanoformulations.
The project NAREB brings together 15 partners (including 4 SMEs and 1 industry) from 8 EU Member and Associated States with outstanding complementary expertise, ranging from material engineering to molecular biology, pharmacology and medicine.'